Momenta Pharmaceuticals, Inc.
MNTA
MNTA was delisted on the 30th of September, 2020.
160 hedge funds and large institutions have $962M invested in Momenta Pharmaceuticals, Inc. in 2016 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 56 increasing their positions, 43 reducing their positions, and 19 closing their positions.
3,213% more call options, than puts
Call options by funds: $1.76M | Put options by funds: $53K
37% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 19
34% more capital invested
Capital invested by funds: $718M → $962M (+$244M)
30% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 43
3% more funds holding
Funds holding: 155 → 160 (+5)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$39M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$9.58M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.92M |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$4.36M |
| 5 |
SC
Samlyn Capital
New York
|
+$3.49M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NRC
North Run Capital
Boston,
Massachusetts
|
-$8.24M |
| 2 |
FCMI
Foresite Capital Management III
Larkspur,
California
|
-$6.96M |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$6.93M |
| 4 |
SAM
Senzar Asset Management
New York
|
-$5.68M |
| 5 |
Fiera Capital (Canada)
Montreal,
Quebec, Canada
|
-$4.86M |
MNTA Hedge Fund Activity: Q4 2016 in Review
160 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Momenta Pharmaceuticals, Inc. (MNTA) for Q4 2016, worth a combined $962M — up 34% from $718M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new MNTA positions and 19 closed out — a net gain of 7 holders — while 56 added to existing stakes and 43 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $39M. The largest seller was North Run Capital, exiting entirely with an estimated $8.24M sold.
- 160 institutional investors held Momenta Pharmaceuticals, Inc. (MNTA) as of Q4 2016, up from 155 in Q3 2016.
- Funds reported $962M of Momenta Pharmaceuticals, Inc. stock for Q4 2016, up 34% quarter-over-quarter.
- 26 funds opened new Momenta Pharmaceuticals, Inc. positions in Q4 2016 and 19 closed out, a net change of +7 holders.
- The largest Momenta Pharmaceuticals, Inc. buyer in Q4 2016 was OrbiMed, an estimated $39M added.
- The largest Momenta Pharmaceuticals, Inc. seller in Q4 2016 was North Run Capital, an estimated $8.24M sold.
Based on aggregated 13F filings for Q4 2016.